Canada Enteral Nutrition Market is expected to reach CA$ 817.11 million by 2031


PRESS RELEASE BY The Insight Partners 22 Apr 2024

Share this press on


Orthopedic Disorders Segment to Dominate Canada Enteral Nutrition Market During 2023–2031 

According to our new research study on "Canada Enteral Nutrition Market Size and Forecast (2021–2031), Country Share, Trend, and Growth Opportunity Analysis," the market value is expected to surge from CA$ 514.33 million in 2023 to CA$ 817.11 million by 2031; the market is anticipated to record a CAGR of 6.0% from 2023 to 2031. Key factors driving the Canada enteral nutrition market growth include the surge in the prevalence of cachexia and related disorders and the rise in the prevalence of gastrointestinal diseases. Further, the specific formulations and plant-based nutrition products are expected to bring new Canada enteral nutrition market trends in the coming years.

Crohn’s disease, gastrointestinal disease due to trauma, bowel obstruction (BO), microscopic colitis, short bowel syndrome, and ulcerative colitis are a few of the common gastrointestinal diseases. According to an article published in Healthline in 2021, ~40% of people across the world were affected by functional gastrointestinal disorders. The Canadian Digestive Health Foundation states millions of Canadians live with digestive diseases; ~20 million Canadians, i.e., 2 of every 3 persons, suffer from digestive disorders yearly. Enteral nutrition helps administer vital nutrients, which helps maintain strength, energy, and hydration levels in cancer patients (all stages).

Canada Enteral Nutrition Market

Canada Enteral Nutrition Market


Canada Enteral Nutrition Market Demand and Forecast | 2031

Download Free Sample

Canada Enteral Nutrition Market Size and Forecast (2021 - 2031), Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Disease Indication (Orthopedic Disorders, Cardiovascular Disorders, Oncology, Neurological Disorders, and Others), Formula Type (Standard Formulas, Peptide Formulas, and Specialized Formulas), Route of Administration (Oral and Tube Feed), and End User (Long Term Care Facilities, Hospitals, and Others)

Crohn’s disease is a complex, chronic disorder that primarily affects the digestive system. The National Library of Medicine stated that there were 825 cases of IBD per 100,000 people in 2023, including 410 cases of Crohn's disease and 414 cases of ulcerative colitis and IBD-u. With a prevalence of 0.82%, 322,600 Canadians had IBD in 2023. Patients with gastrointestinal disease are at an increased risk of nutritional deterioration due to fasting requirements of diagnostic tests, therapeutic dietary restrictions, and loss of appetite due to anorexia or altered nutritional requirements caused due to the disease itself. Thus, enteral nutrition is prescribed for gastrointestinal disease patients, as the enteral route is preferred to provide the required nutrients. Therefore, the growing prevalence of gastrointestinal diseases drives the Canada enteral nutrition market growth.

There is a surge in the demand for products that help consumers proactively manage their health, especially those focused on specific needs in terms of energy levels, immunity, and disease treatment. Pharmaceutical companies provide enteral nutrition with patient-specific constituents. Standardized nutrition products contain fixed constituents and are designed to meet the average nutritional requirements determined by considering varied requirements in different age groups. These nutrition products can be sourced as institution-specific standardized formulations or patient-specific formulations. For example, Impact (offered by Nestle) is a clinically proven nutritional solution for managing patients undergoing major elective surgeries to reduce postoperative complications and hospital stay durations, along with improving clinical outcomes. Peptamen Formula (Nestle) is the only peptide-based formula with enzymatically hydrolyzed 100% whey protein; the product helps overcome tube-feeding intolerance. Such tube-feeding formulae are specialized enteral nutrition products designed to support absorption and overcome tolerance mechanisms in individuals with gastrointestinal disorders. Calogen by Nutricia is a high-energy, oral nutritional supplement containing long-chain triglyceride fat emulsion used to manage conditions requiring a high-energy intake. Thus, specific formulations and plant-based nutrition products are likely to emerge as new Canada enteral nutrition market trends in the coming years.

The Canada enteral nutrition market analysis is carried out by identifying and evaluating key players in the Canadian market. Nestle SA, Abbott Laboratories, Fresenius Medical Care AG & Co KgaA, Koninklijke DSM NV, and B Barun SE are among the prominent players profiled in the Canada enteral nutrition market report. In addition, several other players have been studied and analyzed during the study to get a holistic view of the market and its ecosystem.

The Canada enteral nutrition market forecast can help stakeholders in this marketplace plan their growth strategies. This report emphasizes the key factors driving the market and showcases the developments of prominent players. Major players profiled in the Canada enteral nutrition market report are focused on R&D efforts to proactively introduce new products to meet evolving consumer demands. For instance, in August 2023, Fresenius Kabi designed new labels for enteral nutrition products, these labels have been developed to improve readability and to highlight key information.

The Canada enteral nutrition market has been segmented on the basis of disease indication, formula type, route of administration, and end user. Based on disease indication, the orthopedic disorders segment held the largest Canada enteral nutrition market share in 2023. The cardiovascular disorders segment is anticipated to register the highest CAGR during 2023–2031. Based on formula type, the standard formulas segment held the largest Canada enteral nutrition market share in 2023, and it is anticipated to register a higher CAGR from 2023 to 2031. Based on the route of administration, the oral segment held a larger share of the market in 2023; the same segment is anticipated to register a higher CAGR during 2023–2031. In terms of end users, the long-term care facilities segment is anticipated to account for a significant market share during 2023–2031.

Contact Us
 
Phone: +1-646-491-9876
Email Id: sales@theinsightpartners.com

Download Free PDF Brochure